Recent clinical data shows that patients using semaglutide have experienced an average weight reduction of 15%, which is a remarkable improvement compared to other weight loss treatments
TB4 is classified as a research chemical in the United States and is not FDA-approved for human use outside clinical studies
(2022) demonstrated that combined GLP-1/GIP/glucagon co-agonism produced approximately 3040% greater fat mass reduction in preclinical models compared to GLP-1/GIP dual agonism alone at matched doses
Zhu W, Gregory JC, Org E, Buffa JA, Gupta N, Wang Z, Li L, Fu X, Wu Y, Mehrabian M, et al
Moreover, this condition leads to a low level of intrinsic factor, a protein that prevents vitamin B12 deficiency
It also donates acetyl groups that support the production of neurotransmitters involved in memory, focus, and mood